As part of its ongoing consultation processes on the possibility of the Medicines Patent Pool (MPP) expanding into other disease areas, the organisation has published independent feasibility studies exploring the case for potential entry into hepatitis C and tuberculosis.
MPP commissioned Dalberg and the Center for Disease Analysis for the study on hepatitis C, and Trinity Partners and Elizabeth Gardiner to conduct the analysis for tuberculosis. The consultants were tasked with providing their own strategic assessment of whether and to what extent MPP’s model could be adapted to increase access to new and re-purposed products and promote innovation for new solutions in these areas. They have been reviewed by MPP’s governance bodies.
The two reports posted today are the consultancies’ own views and do not represent the opinions of MPP’s senior leadership nor its Board. They are one step in a process MPP is undertaking to understand the access and innovation challenges in Hep C and TB and a potential MPP contribution to improving health outcomes for patients.
We welcome feedback from all stakeholders. Please send your comments on the reports or any other questions or comments you might feel appropriate to gro.looptnetapsenicidem@noitatlusnoc by July 31. Your opinions will be included in the evaluation that MPP will provide to its funder UNITAID this autumn. The MPP values the opinions of partners and stakeholders and will continue to address concerns and respond to questions on next steps for its possible role in Hep C and TB.
Source: Medicines Patent Pool